All Articles

Is nicotinamide adenine dinucleotide the Achilles’ heel of chronic interleukin-6 signaling in cholangiocarcinoma?

Combining locoregional and systemic therapies in liver cancer: from strategy to survival

An immunocompetent model of hepacivirus-associated liver fibrosis and hepatocellular carcinoma

Metabolic memory and immune evasion in MASLD-HCC progression

Is the second recurrence peak in HBV-related HCC fading in the antiviral era?

Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which

Advancing immunotherapy and tumor microenvironment research in hepatocellular carcinoma

From gut-liver axis hijacking to intratumoral microbiota establishment: mechanisms and therapeutic opportunities in hepatocellular carcinoma

Beyond scarcity: rethinking transplant candidacy in the era of pig-to-human liver xenotransplantation

Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

Evolving epidemiology and antimicrobial resistance in cirrhosis: time for a region-specific approach

Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside

Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Pseudocirrhosis: pathophysiology, clinical mimics, and its role in hepatocellular carcinoma diagnosis and management

Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease

From platforms to pathways: imaging innovation, quantitative biomarkers, and clinical translation in hepatocellular carcinoma

When a hazard ratio is not enough: non-proportional hazards are reshaping the interpretation of phase III trials in hepatocellular carcinoma

Rewiring neurotrophic signaling to escape targeted therapy in hepatocellular carcinoma